| Thursday, June 27, 2024 On the left is a 3D rendering of enterovirus D68 (viral proteins red, yellow, blue) with human monoclonal antibody EV68-228 (orange/purple). To the right in the background is a colorized transmission electron micrograph of enterovirus D68 virus particles (green). 3D rendering by NIAID; micrograph, repositioned and recolored by NIAID, courtesy of CDC. Credit: CDC and NIAID A NIAID-sponsored clinical trial has begun to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and polio-like neurological disease – such as acute flaccid myelitis (AFM). Scientists are striving to better understand AFM, which has emerged in the United States with spikes in cases every other year, primarily in the late-summer months over the last decade. The U.S. Centers for Disease Control and Prevention (CDC) identified increases in AFM cases in 2014, 2016, and 2018. There are no Food and Drug Administration-approved treatments for severe EV-D68 infection or AFM. Clinical Trial NCT06444048 will enroll 36 healthy volunteers ages 18 to 49 at Vanderbilt University Medical Center and the University of Maryland. National Institute of Allergy and Infectious Diseases | National Institutes of Health | | | |
No comments:
Post a Comment